Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 310 • 2018 ACR/ARHP Annual Meeting
The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
Mary-Clair Yelovich¹, Hanyan Zou¹, Siobhan Deshauer¹, Saara Totterman², Karen A. Beattie³ and Maggie Larche⁴, ¹McMaster University, Hamilton, ON, Canada, ²Qmetrics Technologies, Pittsford, NY, ³Medicine, McMaster University, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: The identification of erosions plays a critical role in the management of RA, as the presence of erosions denotes more aggressive disease requiring more…
Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 313 • 2018 ACR/ARHP Annual Meeting
Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia
Aleid C. Boer¹, Sarah Ohrndorf², Debbie M. Boeters¹, Robin M ten Brinck¹, Gerd R. Burmester², Marion Kortekaas¹ and Annette H.M. van der Helm-van Mil^1,3, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: In the diagnostic process of RA, the use of advanced imaging techniques like musculoskeletal ultrasound (US) and magnetic resonance imaging (MRI) has been recommended.…
Abstract Number: 1934 • 2018 ACR/ARHP Annual Meeting
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Isaac T. Cheng¹, Qing Shang², Jiayun Shen³, Martin Li³, Queenie Mak², Kitty Y Kwok⁴, Isaac CW Yim⁵, Edmund Kwok Ming Li², Priscilla Wong¹, Ronald ML Yip⁶, Steve H Pang⁶ and Lai-Shan Tam⁷, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Patients with RA had increased risk of cardiovascular disease (CVD). Interleukin 33 (IL-33) plays an important role in pathogenesis of RA and development of…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Yuhan Zou¹, Peter P.M. Cheung^2,3, Lay Kheng Teoh⁴ and Manjari Lahiri^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ³Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1901 • 2017 ACR/ARHP Annual Meeting
Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Samina A. Turk^1,2, Dirkjan van Schaardenburg^3,4, Maarten Boers^4,5, Sylvia de Boer¹, Cindy Fokker¹, Willem F. Lems^4,5 and Michael Nurmohamed^1,5, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: An unfavorable body composition is often present in chronic arthritis patients. This unfavorable composition is a loss of muscle mass (sarcopenia), with a stable…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 1903 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study
Lydia Ho Pui Tam¹, Qing SHANG², Edmund Li³, Priscilla WONG³, Kitty Y Kwok⁴, Emily W Kun⁵, Issac C Yim⁶, Violet KL Lee⁷, Ronald ML Yip⁸, Steve H Pang⁸, Virginia W Lao⁸, Queenie Mak¹, Tsz Ho CHENG¹, Xerox Lau¹, Tena K. Li⁹, Tracy Y. ZHU¹⁰, PW Alex LEE¹ and Lai-Shan Tam², ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ¹⁰Bone Quality and Health Center of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher incidence of cardiovascular disease (CVD) and prevalence of arterial stiffness (AS) due to chronic inflammation. AS…
Abstract Number: 486 • 2017 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody Reactivities in Treatment NaïVe Early Rheumatoid Arthritis
Maria K. Jonsson^1,2, Aase Hensvold³, Monika Hansson⁴, Linda Mathsson-Alm⁵, Anna-Birgitte Aga², Joseph Sexton², Bjørg-Tilde Fevang^1,6, Siri Lillegraven², Anca I. Catrina³ and Espen A. Haavardsholm^2,7, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁵Thermo Fisher Scientific, Uppsala, Sweden, ⁶Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁷University of Oslo, Oslo, Norway
Background/Purpose: Anti-citrullinated protein antibody (ACPA) reactivities can precede RA onset, and may be involved in the pathogenesis of the disease. We wanted to assess the…
Abstract Number: 1994 • 2017 ACR/ARHP Annual Meeting
Erosion Depth Predicts Erosion Progression in Patients with Early RA: A Longitudinal Analysis Using HR-pQCT
Jiang YUE¹, James F Griffith², Fan XIAO³, Jiankun XU⁴, Ling Qin⁵ and Lai-Shan Tam⁶, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, HONGKONG, Hong Kong, ³Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Bone Quality and Health Centre of the Department of Orthopaedics and Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, hongkong, Hong Kong, ⁶Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: To ascertain the predictors of erosion progression in patients with early RA using high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods: In this prospective study,…
Abstract Number: 918 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Clinical Rule to Facilitate Recognition of Clinical Arthritis By General Practitioners
Robin M ten Brinck¹, Bastiaan T van Dijk², Hanna W van Steenbergen¹, Saskia le Cessie³, Mattijs E Numans⁴ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Department of Medical Statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early treatment of rheumatoid arthritis requires the early detection of arthritis. This is generally done by joint examination and difficult for general practitioners (GPs).…
Abstract Number: 1997 • 2017 ACR/ARHP Annual Meeting
Detection of Progression of Radiographic Damage Despite Early and Targeted Therapy in Inflammatory Arthritis Using High-Resolution Peripheral Quantitative Computed Tomography
Sarah Manske^1,2, Stephanie Finzel³, Steven K. Boyd⁴ and Cheryl Barnabe⁵, ¹Department of Radiology, University of Calgary, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada, ³Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Early initiation of DMARDs and targeted therapy to achieve remission are said to offer the best opportunity to prevent radiographic damage in early inflammatory…
Abstract Number: 922 • 2017 ACR/ARHP Annual Meeting
Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis is a chronic inflammatory process involving progressive destruction of joints. Currently, 30% of rheumatoid arthritis (RA) patients are over the age of…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.